



XYZAL

Levocetirizine dihydrochloride

1. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 5 mg levocetirizine dihydrochloride.

2. PHARMACEUTICAL FORM

White to off-white, oval, film-coated tablet with a Y logo on one side.

3. CLINICAL INFORMATION

3.1 Indications

For the symptomatic treatment of:

- Allergic rhinitis (including persistent allergic rhinitis)
- Chronic idiopathic urticaria

3.2 Dosage and Administration

The film-coated tablet must be taken orally, swallowed whole with liquid and may be taken with or without food. It is recommended to take the daily dose in one single intake.

Duration of use

Intermittent allergic rhinitis (symptoms <4 days/ week or during less than 4 weeks a year) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear.

In case of persistent allergic rhinitis (symptoms >4 days/ week or for more than 4 weeks a year), continuous therapy can be proposed to the patient during the period of exposure to allergens.

There is clinical experience with the use of levocetirizine for treatment periods of at least 6 months. In chronic urticaria and chronic allergic rhinitis, there is clinical experience of use of cetirizine (racemate) for up to one year.

Route of administration

For oral use.

Adults and adolescents 12 years and above

The daily recommended dose is 5 mg (1 film-coated tablet).

Children

Children aged less than 2 years

The administration of levocetirizine to infants and toddlers aged less than 2 years is not recommended (see *Section Warnings and Precautions*).

Children aged 2 to 6 years

For children aged 2 to 6 years no adjusted dosage is possible with the film-coated tablet formulation.

Children aged 6 to 12 years

The daily recommended dose is 5 mg (1 film-coated tablet).

Elderly

Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see *Renal impairment*).

Renal impairment

The dosing intervals must be individualised according to renal function (eGFR – estimated Glomerular Filtration Rate). Refer to the following table and adjust the dose as indicated.

Dosing Adjustment for Patients with Impaired Renal Function:

Group	eGFR (mL/min)	Dosage and frequency
Normal renal function	≥90	5 mg once daily
Mildly decreased renal function	60 – 89	5 mg once daily
Moderately decreased renal function	30 – 59	5 mg once every 2 days
Severely decreased renal function	15 – 29 (not requiring dialysis)	5 mg once every 3 days
End-stage renal disease (ESRD)	<15 (requiring dialysis treatment)	Contraindicated

Hepatic impairment

No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see *Renal impairment*).

3.3 Contraindications

Levocetirizine is contraindicated in:

- Hypersensitivity to levocetirizine, to cetirizine, to hydroxyzine, to any piperazine derivatives or to any of the excipients.
- Patients with end stage renal disease with estimated Glomerular Filtration Rate (eGFR) below 15 mL/min (requiring dialysis treatment).

3.4 Warnings and Precautions

Alcohol

Precaution is recommended with concurrent intake of alcohol (see *Section Interactions*).

Risk of urinary retention

Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as levocetirizine may increase the risk of urinary retention.

Risk of seizure aggravation

Caution should be taken in patients with epilepsy and patients at risk of convulsion as levocetirizine may cause seizure aggravation.

Allergy skin tests

Response to allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them.

Withdrawal syndrome

Pruritus may occur when levocetirizine is stopped even if those symptoms were not present before treatment initiation (see *Section Adverse Reactions*). The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted.

Infants and children under 2 years

Even if some clinical data are available in children aged 6 months to 12 years (see *Sections Adverse Reactions*), these data are not sufficient to support the administration of levocetirizine to infants and toddlers

aged less than 2 years. Therefore, the administration of levocetirizine to infants and toddlers aged less than 2 years is not recommended.

Children aged less than 6 years

The use of the film-coated tablet formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation.

Lactose

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

3.5 Interactions

No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, glipizide, and diazepam).

Theophylline

A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration.

Ritonavir

In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.

Food

The extent of absorption of levocetirizine is not reduced with food, although the rate of absorption is decreased.

Alcohol

In sensitive patients the concurrent administration of cetirizine or levocetirizine and alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.

3.6 Pregnancy and Lactation

Fertility

There are no relevant data available.

Pregnancy

The use of levocetirizine may be considered during pregnancy, if necessary. There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of levocetirizine in pregnant women. However, for cetirizine, the racemate of levocetirizine, a large amount of data (more than 1,000 pregnancy outcomes) on pregnant women indicate no malformative or feto/neonatal toxicity. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development.

Lactation

Caution should be exercised when prescribing to lactating women. Cetirizine, the racemate of levocetirizine, has been shown excreted in human. Therefore, the excretion of levocetirizine in human milk is likely. Adverse reactions associated with levocetirizine may be observed in breastfed infants.

3.7 Ability to Perform Tasks that Require Judgement, Motor or Cognitive Skills

Comparative clinical trials have revealed no evidence that levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive and use machines.

Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy with levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account.

3.8 Adverse Reactions

Clinical trial data

Adults and adolescents above 12 years of age

In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6% of these adverse drug reactions were mild to moderate.

In therapeutic trials, the dropout rate due to adverse events was 1.0% (9/935) with levocetirizine 5 mg and 1.8% (14/771) with placebo. Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the drug at the recommended dose of 5 mg daily.

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency.

Very common	≥1/10
Common	≥1/100 to <1/10
Uncommon	≥1/1,000 to <1/100
Rare	≥1/10,000 to <1/1,000
Very rare	<1/10,000
Not known	(cannot be estimated from the available data)

Nervous system disorders

Common: headache, somnolence

Gastrointestinal disorders

Common: dry mouth

Uncommon: abdominal pain

General disorders and administration site conditions

Common: fatigue

Uncommon: asthenia

The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1%) under levocetirizine 5 mg than under placebo (3.1%).

Post-marketing data

Immune system disorders

Not known: hypersensitivity including anaphylaxis

Metabolism and nutrition disorders

Not known: increased weight, increased appetite

Psychiatric disorders

Not known: aggression, agitation, hallucination, depression, insomnia, suicidal ideation, nightmares

Nervous system disorders

Not known: convulsions, paraesthesia, dizziness, syncope, tremor, dysgeusia

Eye disorders

Not known: visual disturbances, blurred vision, oculogyration

Ear and labyrinth disorders

Not known: vertigo

Cardiac disorders

Not known: palpitations, tachycardia

Respiratory, thoracic and mediastinal disorders

Not known: dyspnoea

Gastrointestinal disorders

Not known: nausea, vomiting, diarrhoea

Hepatobiliary disorders

Not known: hepatitis, abnormal liver function test

Skin and subcutaneous tissue disorders

Not known: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria

Musculoskeletal and connective tissue disorders

Not known: myalgia, arthralgia

Renal and urinary disorders

Not known: dysuria, urinary retention

General disorders and administration site conditions

Not known: oedema

Skin reactions occurring after discontinuation of levocetirizine

After levocetirizine discontinuation, pruritus has been reported (see *Section Warnings and Precautions*).

Adverse events should be reported to GSK Indonesia via website <https://gsk.public.reportum.com> and Pusat Farmakovigilans/MESO Nasional Direktorat Pengawasan Keamanan, Mutu, dan Ekspor Impor Obat, Narkotika, Psikotropika, Prekursor dan Zat Adiktif Badan Pengawas Obat dan Makanan.

Jl. Percetakan Negara No. 23, Jakarta Pusat, 10560

Email: pv-center@pom.go.id

Website: <https://e-meso.pom.go.id/ADR>

3.9 Overdosage**Symptoms and signs**

Symptoms of overdose may include drowsiness in adults. In children, agitation and restlessness may initially occur, followed by drowsiness.

Treatment

There is no known specific antidote to levocetirizine. Should overdose occur, symptomatic or supportive treatment is recommended. Levocetirizine is not effectively removed by hemodialysis.

Further management should be as clinically indicated or as recommended by the national poison centre, where available.

4. CLINICAL PHARMACOLOGY**4.1 Pharmacodynamics****Pharmacotherapeutic group**

Antihistamine for systemic use, piperazine derivative.

ATC code

R06A E09.

Mechanism of action/Pharmacodynamic effects

Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H₁-receptors.

Binding studies revealed that levocetirizine has high affinity for human H₁-receptors ($K_i = 3.2$ nmol/L). Levocetirizine has an affinity 2-fold higher than that of cetirizine ($K_i = 6.3$ nmol/L). Levocetirizine dissociates from H₁-receptors with a half-life of 115 ± 38 min.

After single administration, levocetirizine shows a receptor occupancy of 90% at 4 hours and 57% at 24 hours.

Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.

In vitro studies (Boyden chambers and cell layers techniques) show that levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A pharmacodynamic experimental study *in vivo* (skin chamber technique) showed three main inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced reaction, compared with placebo in 14 adult patients: inhibition of VCAM-1 release, modulation of vascular permeability and a decrease in eosinophil recruitment.

4.2 Pharmacokinetics

The pharmacokinetics of levocetirizine are linear with dose and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when given as cetirizine. No chiral inversion occurs during the process of absorption and elimination.

Absorption

Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two days. Peak concentrations are typically 270 ng/mL and 308 ng/mL following a single and a repeated 5 mg once daily dose, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed.

Distribution

No tissue distribution data are available in humans, neither concerning the passage of levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment. In humans, levocetirizine is 90% bound to plasma proteins. The distribution of levocetirizine is restrictive, as the volume of distribution is 0.4 L/kg.

Metabolism

The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O-dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose.

Due to its low metabolism and absence of metabolic inhibition potential, the interaction of levocetirizine with other substances, or vice-versa, is unlikely.

Elimination

The plasma half-life in adults is 7.9 ± 1.9 hours. The half-life is shorter in small children. The mean apparent total body clearance in adults is 0.63 mL/min/kg. The major route of excretion of levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via faeces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.

Special patient populations

Children

Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that C_{max} and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean C_{max} was 450 ng/mL, occurring at a mean time of 1.2 hours, weight-normalised, total body clearance was 30% greater, and the elimination half-life 24% shorter in this paediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 323 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age is expected to result in plasma concentrations similar to those of adults receiving 5 mg once daily.

Elderly

Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65-74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dose should be adjusted in accordance with renal function in elderly patients.

Renal impairment

The apparent body clearance of levocetirizine is correlated to the creatinine clearance. It is therefore recommended to adjust the dosing intervals of levocetirizine, based on creatinine clearance in patients with moderate and severe renal impairment. In anuric end stage renal disease subjects, the total body clearance is decreased by approximately 80% when compared to normal subjects. The amount of levocetirizine removed during a standard 4-hour hemodialysis procedure was <10%.

Hepatic impairment

The pharmacokinetics of levocetirizine in hepatically impaired subjects have not been tested. Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half-life along with a 40% decrease in clearance compared to healthy subjects.

Other patient characteristics

Gender

Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 ± 1.72 hr) than in men (8.62 ± 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 ± 0.16 mL/min/kg) appears to be comparable to that in men (0.59 ± 0.12 mL/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.

Race

The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.

4.3 Clinical Studies

The efficacy and safety of levocetirizine has been demonstrated in several double-blind, placebo-controlled, clinical trials performed in adult patients suffering from seasonal allergic rhinitis, perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some studies.

A 6-month clinical study in 551 adult patients (including 276 levocetirizine-treated patients) suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4 consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on the relief from the total symptom score of allergic rhinitis throughout the whole duration of the study, without any tachyphylaxis. During the whole duration of the study, levocetirizine significantly improved the quality of life of the patients.

In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic urticaria, 85 patients were treated with placebo and 81 patients with levocetirizine 5 mg once daily over six weeks. Treatment with levocetirizine resulted in significant decrease in pruritus severity over the first week and over the total treatment period as compared to placebo. Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed by the Dermatology Life Quality Index as compared to placebo.

Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histamine release is a causal factor in urticarial diseases, levocetirizine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria.

ECGs did not show relevant effects of levocetirizine on QT interval.

Pharmacokinetic/pharmacodynamic relationship:

The action on histamine-induced skin reactions is out of phase with the plasma concentrations.

Paediatric population

The paediatric safety and efficacy of levocetirizine tablets has been studied in two placebo-controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and perennial allergic rhinitis, respectively. In both trials, levocetirizine significantly improved symptoms and increased health-related quality of life.

5. NON-CLINICAL INFORMATION

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

6. PHARMACEUTICAL INFORMATION

6.1 Shelf Life

The expiry date is indicated on the packaging.

6.2 Storage Condition

Store below 30°C.

Keep out of the reach and sight of children.

Do not use after the expiry date stated on the carton box and blister.

6.3 Nature and Contents of Container

As registered locally.

6.4 Incompatibilities

There are no relevant data available.

6.5 Use and Handling

There are no special requirements for use or handling of this product.

6.6 List of Excipients

Microcrystalline cellulose, colloidal anhydrous silica, lactose monohydrate, magnesium stearate, Opadry Y-I 7000.

Xyzal 5 mg

Box, 5 aluminium blisters @ 10 film-coated tablets

Reg. No. DK11005500609A1

HARUS DENGAN RESEP DOKTER

Manufactured by
UCB Farchim SA
Bulle, Switzerland

Packaged by
Aesica Pharmaceuticals S.r.L
Pianezza, Italy

Imported by
PT Glaxo Wellcome Indonesia
Jakarta, Indonesia

Version number : 01
Reference : NCDS ver. 08 (04 September 2022) + BPOM input on 20 Jul 2025
Date of local revision : 30 November 2025

Trademarks are owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor.